Broadening oncological boundaries: the intratumoral microbiota

Lu, Ying-Qi; Qiao, Han; Tan, Xi-Rong; Liu, Na

doi:10.1016/j.tim.2024.01.007

Cited by 3 publications

(1 citation statement)

References 112 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Emerging evidence supports the role of the oesophageal microbiome in modulating responses to immune checkpoint inhibitors in EC, with different microbial compositions correlating with varying responses to radiotherapy and chemotherapy [161,169,170]. These insights underscore the intricate relationship between intratumoral bacteria and the host immune system in EC, highlighting the potential of microbiome-targeted therapies to complement traditional cancer treatments and improve therapeutic efficacy and patient outcomes [171,172].…”

Section: Roles and Mechanisms Of Bacteria In Ecmentioning

confidence: 82%

Unravelling the role of intratumoral bacteria in digestive system cancers: current insights and future perspectives

Lu,

Aihaiti,

Abudukeranmu

et al. 2024

J Transl Med

View full text Add to dashboard Cite

Recently, research on the human microbiome, especially concerning the bacteria within the digestive system, has substantially advanced. This exploration has unveiled a complex interplay between microbiota and health, particularly in the context of disease. Evidence suggests that the gut microbiome plays vital roles in digestion, immunity and the synthesis of vitamins and neurotransmitters, highlighting its significance in maintaining overall health. Conversely, disruptions in these microbial communities, termed dysbiosis, have been linked to the pathogenesis of various diseases, including digestive system cancers. These bacteria can influence cancer progression through mechanisms such as DNA damage, modulation of the tumour microenvironment, and effects on the host’s immune response. Changes in the composition and function within the tumours can also impact inflammation, immune response and cancer therapy effectiveness. These findings offer promising avenues for the clinical application of intratumoral bacteria for digestive system cancer treatment, including the potential use of microbial markers for early cancer detection, prognostication and the development of microbiome-targeted therapies to enhance treatment outcomes. This review aims to provide a comprehensive overview of the pivotal roles played by gut microbiome bacteria in the development of digestive system cancers. Additionally, we delve into the specific contributions of intratumoral bacteria to digestive system cancer development, elucidating potential mechanisms and clinical implications. Ultimately, this review underscores the intricate interplay between intratumoral bacteria and digestive system cancers, underscoring the pivotal role of microbiome research in transforming diagnostic, prognostic and therapeutic paradigms for digestive system cancers.

show abstract

Section: Roles and Mechanisms Of Bacteria In Ecmentioning

confidence: 82%

Unravelling the role of intratumoral bacteria in digestive system cancers: current insights and future perspectives

Lu,

Aihaiti,

Abudukeranmu

et al. 2024

J Transl Med

View full text Add to dashboard Cite

show abstract

Exploring the Relationship between MicroRNAs, Intratumoral Microbiota, and Breast Cancer Progression in Patients with and without Metastasis

Laborda-Illanes,

Aranega-Martín,

Sánchez-Alcoholado

et al. 2024

IJMS

View full text Add to dashboard Cite

Breast cancer (BC) continues to pose a significant burden on global cancer-related morbidity and mortality, primarily driven by metastasis. However, the combined influence of microRNAs (miRNAs) and intratumoral microbiota on BC metastasis remains largely unexplored. In this study, we aimed to elucidate the interplay between intratumoral microbiota composition, miRNA expression profiles, and their collective influence on metastasis development in BC patients by employing 16S rRNA sequencing and qPCR methodologies. Our findings revealed an increase in the expression of miR-149-5p, miR-20b-5p, and miR-342-5p in metastatic breast cancer (Met-BC) patients. The Met-BC patients exhibited heightened microbial richness and diversity, primarily attributed to diverse pathogenic bacteria. Taxonomic analysis identified several pathogenic and pro-inflammatory species enriched in Met-BC, contrasting with non-metastatic breast cancer (NonMet-BC) patients, which displayed an enrichment in potential probiotic and anti-inflammatory species. Notably, we identified and verified a baseline prognostic signature for metastasis in BC patients, with its clinical relevance further validated by its impact on overall survival. In conclusion, the observed disparities in miRNA expression and species-level bacterial abundance suggest their involvement in BC progression. The development of a prognostic signature holds promise for metastasis risk assessment, paving the way for personalized interventions and improved clinical outcomes in BC patients.

show abstract

Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma: What Should We Focus on to Improve the Clinical Outcomes?

Hossain,

Ly,

Sung

et al. 2024

IJMS

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) have transformed cancer treatment by enhancing anti-tumour immune responses, demonstrating significant efficacy in various malignancies, including melanoma. However, over 50% of patients experience limited or no response to ICI therapy. Resistance to ICIs is influenced by a complex interplay of tumour intrinsic and extrinsic factors. This review summarizes current ICIs for melanoma and the factors involved in resistance to the treatment. We also discuss emerging evidence that the microbiota can impact ICI treatment outcomes by modulating tumour biology and anti-tumour immune function. Furthermore, microbiota profiles may offer a non-invasive method for predicting ICI response. Therefore, future research into microbiota manipulation could provide cost-effective strategies to enhance ICI efficacy and improve outcomes for melanoma patients.

show abstract

Broadening oncological boundaries: the intratumoral microbiota

Cited by 3 publications

References 112 publications

Unravelling the role of intratumoral bacteria in digestive system cancers: current insights and future perspectives

Unravelling the role of intratumoral bacteria in digestive system cancers: current insights and future perspectives

Exploring the Relationship between MicroRNAs, Intratumoral Microbiota, and Breast Cancer Progression in Patients with and without Metastasis

Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma: What Should We Focus on to Improve the Clinical Outcomes?

Contact Info

Product

Resources

About